An Emerging Precision Medicine Modality to Treat Solid Tumors
BNCT holds the potential to overcome poor survival rates for patients with a variety of cancers
Boron neutron capture therapy (BNCT) was initially conceived in the early 20th century. Due to recent advances in boron medicinal chemistry and targeted delivery of safe neutrons, the technology has shown great promise for treating patients with solid tumors.
Despite improvements in cancer outcomes over recent decades, there is still a high unmet clinical need for effective treatments. Cytotoxic drugs, traditional radiation therapies and immunotherapies are limited in their effectiveness and can result in adverse side effects. Boron neutron capture therapy is a precision medicine approach to destroy cancerous cells while leaving healthy cells unharmed.
Together with advanced neutron delivery technologies, BNCT medicines have the ability to precisely target tumors
Potentially fewer treatments
Studies have shown that BNCT has the potential to destroy tumors in fewer treatments compared to other modalities
Low intrinsic toxicity
Boron medicines are designed to be non-toxic and are only activated by safe, low-energy neutrons at the tumor
A potentially safe, efficacious and convenient treatment option
Boron neutron capture therapy has been approved by the Pharmaceuticals and Medical Devices Agency (PMDA) in Japan for unresectable advanced or recurrent head and neck cancer. Additional clinical research on BNCT is being conducted at 16 BNCT treatment centers worldwide.
If you would like to learn more about partnering to expand access to BNCT, please get in touch.
We partner with chemists, biologists and other biopharma companies to develop next generation BNCT medicines.
We are building partnerships with leading medical centers to provide BNCT care to patients.